Skip to main content
OpenTrials
Completed

NCT Number: NCT00320099

Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock

This study will compare, in adults with septic shock, the safety and efficacy of a combination of moderate doses of corticosteroids and intensive insulin therapy to that of moderate doses of corticosteroids. In addition, this study will compare the efficacy and safety of hydrocortisone alone versus hydrocortisone plus fludrocortisone

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hôpital Avicenne, Bobigny, France

Loading trial locations.

About this study

Objectives:

Comparison, in patients with septic shock, of efficacy and safety of the combination of moderate doses of corticosteroids and intensive insulin therapy to that of moderate doses of corticosteroids; and of efficacy and safety of hydrocortisone alone versus hydrocortisone plus fludrocortisone Methods

Study design :

This is a multicenter, prospective, randomised trial on parallel groups

Study treatments :

Experimental arm A:

A1=50 mg iv every 6 hours of hydrocortisone (hemisuccinate), 50µg through the nasogastric tube of 9 alpha fludrocortisone, for 7 days AND strict control of blood glucose levels with a target of 4,4 to 6 mmol/L using continuous iv infusion of insulin up to intensive care unit discharge.

A2=50 mg iv every 6 hours of hydrocortisone (hemisuccinate) for 7 days AND strict control of blood glucose levels with a target of 4,4 to 6 mmol/L using continuous iv infusion of insulin up to intensive care unit discharge.

Control arm B:

B1:50 mg iv every 6 hours of hydrocortisone (hemisuccinate), 50µg through the nasogastric tube of 9 alpha fludrocortisone, for 7 days.

B2:50 mg iv every 6 hours of hydrocortisone (hemisuccinate)for 7 days. Study Primary outcome : In-hospital mortality

Sample size calculation :

The expected in-hospital mortality rate in the control group is 50%. To detect an absolute reduction in in-hospital mortality rate of 12.5 %, that is 37.5% in the experimental arm versus 50% in the control arm, and considering risk alpha of 0,05 and a risk beta of 0,20, 254 patients per treatment arms are needed, for a total of 508 patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients admitted in intensive care units for septic shock and meeting all following criteria

  • Proven infection
  • Need for vasopressor to maintain systemic arterial tension above 90 mmHg
  • Multiple organ dysfunction as defined by a SOFA score ³ 8.
  • Need for treatment with moderate dose of corticosteroids

Exclusion criteria

One of the following :

  • Pregnancy
  • Less than 18 years old
  • Moribund (i.e. expected to die on day of intensive care unit admission)

Treatment and study plan

recombinant human insulin

Drug

intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l

Hydrocortisone

Drug

50 mg as iv bolus every 6 hours for 7 days

fludrocortisone

Drug

50 µg once a day via a nasogastric tube for seven days

Primary outcomes

  1. In-hospital mortality

    Time frame: Day 180

Secondary outcomes

  1. Secondary outcomes :

    Time frame: Day 180

  2. 90-day and 180-day mortality.

    Time frame: Day 180

  3. Duration of life-supporting treatments (i.e. vasopressors and mechanical ventilation)

    Time frame: Day 180

  4. Time to resolve multiple organ dysfunction, i.e. to obtain a SOFA score < 8

    Time frame: Day 180

  5. Hospital length of stay.

    Time frame: Day 180

  6. Number of hypoglycaemic events (blood glucose < 4 mmol/l) during insulin infusion

    Time frame: Day 180

  7. Muscle weakness at discharge from intensive care unit, 90-day and 180-day

    Time frame: Day 180

  8. Post traumatic stress disorders

    Time frame: Day 180

Sponsors and collaborators

Lead sponsor

University of Versailles

Other

Collaborators

  • Assistance Publique - Hôpitaux de Paris

Registry information

Official study title

Phase 3 Study of Corticotherapy (Hydrocortisone Alone Versus Hydrocortisone Plus Fludrocortisone) Versus Corticotherapy Plus Intensive Insulin Therapy for Septic Shock

Acronym: COIITSS

Important dates

Study start
2006
Primary completion
2009
Study completion
2009
First posted
May 3, 2006
Registry last updated
Apr 6, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.